Vertex Pharmaceuticals Incorporated
HealthcareNASDAQ:VRTX · NASDAQ Global Select
-$0.12 today
Vol 0.92M · Avg 1.26M
Income Statement
Follow revenue through to earnings
Review sales, margins, expenses, and profit trends to see what is actually driving reported earnings over time.
Earnings Waterfall
Revenue to Net Income
Key Ratios
Analysis
$12.3B of revenue converted into $4.3B of net income for the selected period. Gross margin is 86.3% and net margin is 35.4%, showing how much revenue survives after costs and taxes. EPS is $16.86, tying the income statement back to per-share earnings.
Income Statement
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $12.1B +9.6% | $11.0B +11.7% | $9.9B +10.5% | $8.9B +17.9% | $7.6B | $809.6M | $921.6M | $731.2M |
| Cost of Revenue | $1.8B +18.1% | $1.5B +21.3% | $1.3B +16.8% | $1.1B +19.5% | $904.2M | $725.6M | $804.0M | $882.4M |
| Gross Profit | $10.3B +8.2% | $9.5B +10.3% | $8.6B +9.6% | $7.9B +17.7% | $6.7B | $8.9B | $7.6B | $6.2B |
| Gross Margin | 85.0% -1.1pp | 86.1% -1.1pp | 87.2% -0.7pp | 87.9% -0.2pp | 88.1% | 9.8% | 28.9% | 38.3% |
| Research & Development | $3.8B +3.4% | $3.6B +14.8% | $3.2B +19.1% | $2.7B -13.0% | $3.1B | $983.2M | $1.3B | $490.4M |
| Selling, General & Admin | $1.8B +19.7% | $1.5B +28.8% | $1.1B +20.3% | $944.7M +12.5% | $840.1M | $620.6M | $923.0M | -$1.5B |
| Operating Expenses | $5.5B -43.4% | $9.7B +103.6% | $4.8B +34.8% | $3.5B -8.9% | $3.9B | $5.3B | $7.0B | $8.7B |
| Depreciation & Amortization | $207.2M +0.7% | $205.8M +13.5% | $181.3M +22.3% | $148.3M +18.1% | $125.6M | $374.2M | $1.2B | $631.8M |
| EBITDA | $4.9B +900.1% | $486.3M -89.4% | $4.6B +3.8% | $4.4B +52.0% | $2.9B | -$15.2B | $6.8B | $9.3B |
| EBITDA Margin | 40.3% +35.9pp | 4.4% -42.2pp | 46.7% -3.0pp | 49.7% +11.1pp | 38.5% | 5.6% | 46.3% | 42.0% |
| Operating Income | $4.8B +2144.1% | -$232.9M -106.1% | $3.8B -11.0% | $4.3B +54.8% | $2.8B | $12.3B | $14.0B | -$15.7B |
| Operating Margin | 39.4% +41.5pp | -2.1% -40.9pp | 38.8% -9.4pp | 48.2% +11.5pp | 36.7% | 16.6% | 24.1% | 22.0% |
| Interest Income | $490.9M -17.9% | $598.1M -2.7% | $614.7M +325.1% | $144.6M +2851.0% | $4.9M | -$1.5B | -$1.6B | $405.0M |
| Interest Expense | $13.3M -56.5% | $30.6M -30.6% | $44.1M -19.5% | $54.8M -10.9% | $61.5M | $1.1B | $1.0B | $1.2B |
| Other Income / Expenses | -$117.5M -124.4% | $481.4M -12.1% | $547.8M +830.4% | -$75.0M -45.1% | -$51.7M | -$1.5B | $1.4B | $1.2B |
| Income Before Tax | $4.6B +1768.5% | $248.5M -94.3% | $4.4B +3.5% | $4.2B +55.0% | $2.7B | $3.3B | $4.9B | $3.6B |
| Pre-Tax Margin | 38.5% +36.2pp | 2.3% -42.1pp | 44.4% -3.0pp | 47.4% +11.3pp | 36.0% | 20.8% | 18.7% | 26.2% |
| Income Tax Expense | $690.0M -12.0% | $784.1M +3.1% | $760.2M -16.5% | $910.4M +134.5% | $388.3M | $1.3B | -$1.6B | $745.2M |
| Net Income | $4.0B +838.1% | -$535.6M -114.8% | $3.6B +9.0% | $3.3B +41.8% | $2.3B | $4.9B | $4.8B | $4.7B |
| Net Margin | 32.7% +37.6pp | -4.9% -41.5pp | 36.7% -0.5pp | 37.2% +6.3pp | 30.9% | 12.4% | 17.5% | 22.5% |
| EPS (Basic) | $15 +843.3% | -$2 -114.8% | $14 +8.3% | $13 +42.7% | $9 | $400.8M | $703.2M | $1.3B |
| EPS (Diluted) | $15 +836.5% | -$2 -115.0% | $14 +8.3% | $13 +42.3% | $9 | $766.2M | $609.4M | $452.6M |
| Weighted Avg Shares | $255.7M -0.7% | $257.5M -0.1% | $257.7M +0.6% | $256.1M -0.6% | $257.7M | $757.8M | $925.8M | $1.1B |
| Weighted Avg Shares (Diluted) | $258.0M +0.0% | $257.9M -1.0% | $260.5M +0.5% | $259.1M -0.3% | $259.9M | $1.2B | $924.4M | $678.0M |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
CVS Health Corporation
NYSE:CVS
$130.09B
Stryker Corporation
NYSE:SYK
$119.69B
Bristol-Myers Squibb Company
NYSE:BMY
$116.66B
Sanofi
NASDAQ:SNY
$106.39B
GSK plc
NYSE:GSK
$106.31B
Medtronic plc
NYSE:MDT
$102.97B
McKesson Corporation
NYSE:MCK
$94.25B
HCA Healthcare, Inc.
NYSE:HCA
$85.89B
Regeneron Pharmaceuticals, Inc.
NASDAQ:REGN
$63.06B
argenx SE
NASDAQ:ARGX
$55.29B
SEC Filings
Recent regulatory filings
No filings found.
How much revenue does VRTX generate?
Vertex Pharmaceuticals Incorporated (VRTX) reported $12.07B of revenue in fiscal 2025.
Is VRTX profitable?
Vertex Pharmaceuticals Incorporated (VRTX) reported $3.95B of net income, with a net margin of 32.7%.
Explore More
Continue the stock analysis
Jump to another research area for this company.